| |
Develop a commercial value creation story to differentiate your product and attract investors by leveraging our deep commercialization experience. Download the guide now.
|
|
Today’s Big NewsJun 10, 2025 |
|
In a capital-constrained environment, equipment financing offers a smart and flexible path forward. NFS Capital is here to help you keep innovating without waiting for your next funding round. Request more information.
|
|
| By Ben Adams Gilead has been hit with a clinical hold from the FDA for five tests of its experimental HIV combination treatment amid safety concerns. |
|
|
|
By Eric Sagonowsky The Department of Health and Human Services has removed all 17 sitting members of the CDC's Advisory Committee on Immunization Practices. |
By Nick Paul Taylor Pfizer CEO Albert Bourla has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing that his team went through individual scans and interviewed investigators to gain reassurance about the quality of the Chinese data. |
Sponsored by WCG When clinical trial steps are managed separately, the study suffers from compounded delays. Discover proven solutions from trusted industry experts. |
By Gabrielle Masson After Eli Lilly snapped up Scorpion’s PI3Kα program earlier this year, the biotech is selling off its other two clinical assets and spinning out a new company to advance its three preclinical precision medicine candidates. |
Sponsored by Invest Puerto Rico Global trade uncertainty and evolving tariff policies are shifting how bioscience companies view their supply chains. |
By James Waldron Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. |
By James Waldron Keros Therapeutics’ pledge to hand $375 million to shareholders has not been enough to appease activist investor demands to slash further costs just weeks after the biotech laid off staff. |
By James Waldron Odyssey Therapeutics has bailed on its long-awaited public listing in further evidence that the IPO window remains firmly shut for now. |
By Darren Incorvaia Hundreds of staffers at the National Institutes of Health (NIH) are urging agency Director Jay Bhattacharya, Ph.D., to reverse the drastic changes made within the last five months, including the termination of about $9.5 billion in federal research grants. Since President Donald Trump's inauguration, the NIH has ended 2,100 research grants worth around $9.5 billion and contracts worth $2.6 billion, the authors wrote in the June 9 Bethesda Declaration. |
By Darren Incorvaia Axsome Therapeutics has hit a costly snag in its mission to bring esreboxetine to market for fibromyalgia. The FDA has refused to review the CNS specialist’s new drug application for the asset, with the agency determining that one of the two trials in the filing was not up to snuff. |
By Kevin Dunleavy National Resilience is consolidating its CDMO business, closing six of its plants and continuing to operate as a streamlined company at four sites, including its anchor facility in Cincinnati. |
By Heather Landi The company has four nonbinding bids for its Banmédica subsidiary, which operates in Colombia and Chile, for about $1 billion, Reuters reported, citing two people with direct knowledge of the matter. |
By Kevin Dunleavy The FDA has blessed Merck’s clesrovimab to protect against lower respiratory tract disease related to respiratory syncytial virus in newborns and infants. The monoclonal antibody, which will be known commercially as Enflonsia, will challenge Sanofi and AstraZeneca’s blockbuster Beyfortus. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," the Fierce team reports from ASCO, highlighting key takeaways on clinical data, standout campaigns and buzz from the exhibit floor. |
|
|---|
|
|
|
From gene therapy pipelines to early-stage VC deals, biotech leaders are seeking clarity in the chaos. That’s why companies are sharing their insights through Fierce content hubs — with weekly features right here in your inbox. See how others are shaping the narrative.
|
|
| WhitepaperWe analyzed ~300 launches to identify the factors most correlated with commercial success & built a framework for peak go-to-market performance. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
